Viking Therapeutics, Inc. (VKTX) stock
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.88+0.08 (+0.30%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Viking Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Viking Therapeutics's total assets was $977.17M at Sep 30, 2026. For fiscal 2025 it was $715.73M, down 21.2% from the year before. Over ten years it grew 46.8% a year on average. The highest annual figure on record is $908.32M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $715.73M | -21.2% |
| FY2024 | Dec 31, 2024 | $908.32M | +146.5% |
| FY2023 | Dec 31, 2023 | $368.49M | +118.7% |
| FY2022 | Dec 31, 2022 | $168.53M | -20.0% |
| FY2021 | Dec 31, 2021 | $210.66M | -17.9% |
| FY2020 | Dec 31, 2020 | $256.50M | -9.8% |
| FY2019 | Dec 31, 2019 | $284.26M | -6.0% |
| FY2018 | Dec 31, 2018 | $302.31M | +1266.6% |
| FY2017 | Dec 31, 2017 | $22.12M | +52.2% |
| FY2016 | Dec 31, 2016 | $14.54M | -5.9% |
| FY2015 | Dec 31, 2015 | $15.44M | +407.3% |
| FY2014 | Dec 31, 2014 | $3.04M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $977.17M | +32.2% |
| Q2 FY2026 | Jun 30, 2026 | $521.90M | -37.0% |
| Q1 FY2026 | Mar 31, 2026 | $608.24M | -29.8% |
| Q4 FY2025 | Dec 31, 2025 | $715.73M | -21.2% |
| Q3 FY2025 | Sep 30, 2025 | $739.42M | -21.2% |
| Q2 FY2025 | Jun 30, 2025 | $827.85M | -12.6% |
| Q1 FY2025 | Mar 31, 2025 | $866.99M | -10.4% |
| Q4 FY2024 | Dec 31, 2024 | $908.32M | +146.5% |
| Q3 FY2024 | Sep 30, 2024 | $937.89M | +145.1% |
| Q2 FY2024 | Jun 30, 2024 | $946.84M | +136.3% |
| Q1 FY2024 | Mar 31, 2024 | $967.52M | +541.2% |
| Q4 FY2023 | Dec 31, 2023 | $368.49M | +118.7% |
| Q3 FY2023 | Sep 30, 2023 | $382.66M | +129.6% |
| Q2 FY2023 | Jun 30, 2023 | $400.69M | +120.8% |
| Q1 FY2023 | Mar 31, 2023 | $150.90M | -22.6% |
| Q4 FY2022 | Dec 31, 2022 | $168.53M | -20.0% |
| Q3 FY2022 | Sep 30, 2022 | $166.68M | -25.7% |
| Q2 FY2022 | Jun 30, 2022 | $181.51M | -23.7% |
| Q1 FY2022 | Mar 31, 2022 | $195.03M | -22.0% |
| Q4 FY2021 | Dec 31, 2021 | $210.66M | -17.9% |
| Q3 FY2021 | Sep 30, 2021 | $224.47M | -14.9% |
| Q2 FY2021 | Jun 30, 2021 | $237.85M | -12.3% |
| Q1 FY2021 | Mar 31, 2021 | $250.14M | -9.7% |
| Q4 FY2020 | Dec 31, 2020 | $256.50M | -9.8% |
| Q3 FY2020 | Sep 30, 2020 | $263.62M | -9.1% |
| Q2 FY2020 | Jun 30, 2020 | $271.20M | -7.9% |
| Q1 FY2020 | Mar 31, 2020 | $277.10M | -7.7% |
| Q4 FY2019 | Dec 31, 2019 | $284.26M | -6.0% |
| Q3 FY2019 | Sep 30, 2019 | $290.12M | -5.4% |
| Q2 FY2019 | Jun 30, 2019 | $294.49M | +103.8% |
| Q1 FY2019 | Mar 31, 2019 | $300.08M | +280.0% |
| Q4 FY2018 | Dec 31, 2018 | $302.31M | +1266.6% |
| Q3 FY2018 | Sep 30, 2018 | $306.80M | +2491.3% |
| Q2 FY2018 | Jun 30, 2018 | $144.47M | +908.8% |
| Q1 FY2018 | Mar 31, 2018 | $78.97M | +421.2% |
| Q4 FY2017 | Dec 31, 2017 | $22.12M | +52.2% |
| Q3 FY2017 | Sep 30, 2017 | $11.84M | – |
| Q2 FY2017 | Jun 30, 2017 | $14.32M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.15M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.54M | – |
See a number that looks wrong?